Definium Therapeutics CFO Brandi Roberts Buys Shares

Brandi Roberts, the Chief Financial Officer of Definium Therapeutics, Inc. (NasdaqGS:DFTX), purchased 62,500 shares of the company on June 22, 2026. This transaction took place as part of an open market purchase, and the shares were acquired at no disclosed price. Shares of Definium traded near $24.48 on Monday.

Insider Buying and Selling at Definium Therapeutics, Inc.

In addition to Brandi Roberts, several other insiders at Definium Therapeutics made purchases on June 22, 2026. CEO Robert Barrow acquired 375,000 shares, while Chief Medical Officer Karlin Daniel bought 100,000 shares. Chief Legal Officer Mark Sullivan, Chief Commercial Officer Matthew Wiley, and Andreas Krebs also made purchases, with each buying 62,500 shares, except for Krebs, who bought 19,188 shares earlier on June 11, 2026. None of these transactions were part of a pre-arranged trading plan.

Other Institutional Activity in Definium Therapeutics

Several institutional investors have shown interest in Definium Therapeutics recently. BlackRock, Inc. opened a new position with 8,480,230 shares valued at about $160.3 million. Similarly, Avoro Capital Advisors LLC and Janus Henderson Group PLC both initiated new stakes, acquiring 5,000,000 and 3,556,041 shares, respectively, with corresponding values of approximately $94.5 million and $67.2 million. Meanwhile, Driehaus Capital Management LLC reduced its holdings by 625,313 shares, resulting in a 9.6% decrease, leaving it with 5,911,889 shares worth around $111.7 million.

Definium Therapeutics, Inc. Stock Down 10.5%

As of Monday, shares of Definium Therapeutics traded at $24.48. The company, with a market cap of roughly $2.67 billion, operates in the volatile biotechnology sector. It has a 52-week range between $6.35 and $26.25. The stock's 50-day moving average is $22.61, and the 200-day moving average is $16.28. Definium's forward P/E is not meaningful as the company is not currently profitable, with negative earnings per share of $2.50.

Analysts Set New Price Targets

Analysts have been active with their ratings on Definium Therapeutics. On June 16, 2026, Canaccord Genuity maintained its 'buy' rating with a price target of $38. Piper Sandler also maintained its 'buy' rating with a $48 target on May 8, 2026. The consensus among 15 analysts is a 'strong buy', with an average price target of $39.87, ranging from $25 to $70.

About Definium Therapeutics

Definium Therapeutics, Inc., based in New York, is a biotechnology company specializing in developing treatments for brain health disorders. Its lead products include DT120, in phase 3 trials for anxiety and depression, and DT402, in phase 2a trials for autism spectrum disorder. The company, led by CEO Robert Barrow, employs 105 people and aims to address unmet needs in the healthcare sector.

Bottom Line

The recent insider purchases at Definium Therapeutics, including those by CFO Brandi Roberts, highlight confidence in the company's prospects. While 13F filings provide a snapshot of institutional activity, they are backward-looking and may not reflect current positions. Investors keep an eye on insider transactions and analyst ratings to gauge potential future performance.